Literature DB >> 23217123

Truncating mutations in FUS/TLS give rise to a more aggressive ALS-phenotype than missense mutations: a clinico-genetic study in Germany.

S Waibel1, M Neumann2, A Rosenbohm1, A Birve3, A E Volk4, J H Weishaupt1, T Meyer5, U Müller6, P M Andersen1,3, A C Ludolph1.   

Abstract

BACKGROUND AND
PURPOSE: Mutations in the FUS/TLS have been associated with amyotrophic lateral sclerosis (ALS) in a few percent of patients.
METHODS: We screened 184 familial (FALS) and 200 sporadic German patients with ALS for FUS/TLS mutations by sequence analysis of exons 5, 6 and 13-15. We compared the phenotypes of patients with different FUS/TLS mutations.
RESULTS: We identified three missense mutations p.K510R, p.R514G, p.R521H, and the two truncating mutations p.R495X and p.G478LfsX23 in samples from eight pedigrees. Both truncating mutations were associated with young onset and very aggressive disease courses, whereas the p.R521H, p.R514G and in particular the p.K510R mutation showed a milder phenotype with disease durations ranging from 3 years to more than 26 years, the longest reported for a patient with a FUS/TLS mutation. Also, in a pair of monozygous twins with the p.K510R mutation, a remarkable similar disease course was observed.
CONCLUSIONS: Mutations in FUS/TLS account for 8.7% (16 of 184) of FALS in Germany. This is a higher prevalence than reported from other countries. Truncating FUS/TLS mutations result in a more severe phenotype than most missense mutations. The wide phenotypic differences have implications for genetic counselling.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23217123     DOI: 10.1111/ene.12031

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  34 in total

1.  Quantitative proteomics identifies proteins that resist translational repression and become dysregulated in ALS-FUS.

Authors:  Desiree M Baron; Tyler Matheny; Yen-Chen Lin; John D Leszyk; Kevin Kenna; Katherine V Gall; David P Santos; Maeve Tischbein; Salome Funes; Lawrence J Hayward; Evangelos Kiskinis; John E Landers; Roy Parker; Scott A Shaffer; Daryl A Bosco
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

Review 2.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 3.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

4.  Mutations in SOD1 and FUS caused juvenile-onset sporadic amyotrophic lateral sclerosis with aggressive progression.

Authors:  Zhang-Yu Zou; Ming-Sheng Liu; Xiao-Guang Li; Li-Ying Cui
Journal:  Ann Transl Med       Date:  2015-09

5.  FUScinating insights into motor neuron degeneration.

Authors:  Dorothee Dormann
Journal:  EMBO J       Date:  2016-04-06       Impact factor: 11.598

6.  FUS Regulates Activity of MicroRNA-Mediated Gene Silencing.

Authors:  Tao Zhang; Yen-Ching Wu; Patrick Mullane; Yon Ju Ji; Honghe Liu; Lu He; Amit Arora; Ho-Yon Hwang; Amelia F Alessi; Amirhossein G Niaki; Goran Periz; Lin Guo; Hejia Wang; Elad Elkayam; Leemor Joshua-Tor; Sua Myong; John K Kim; James Shorter; Shao-En Ong; Anthony K L Leung; Jiou Wang
Journal:  Mol Cell       Date:  2018-03-01       Impact factor: 17.970

7.  Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1.

Authors:  Michael Tibshirani; Miranda L Tradewell; Katie R Mattina; Sandra Minotti; Wencheng Yang; Hongru Zhou; Michael J Strong; Lawrence J Hayward; Heather D Durham
Journal:  Hum Mol Genet       Date:  2014-09-30       Impact factor: 6.150

8.  De novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case.

Authors:  Andrea Calvo; Cristina Moglia; Antonio Canosa; Maura Brunetti; Marco Barberis; Bryan J Traynor; Giovanna Carrara; Consuelo Valentini; Gabriella Restagno; Adriano Chiò
Journal:  Neurobiol Aging       Date:  2013-12-27       Impact factor: 4.673

Review 9.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

10.  Low Level of Expression of C-Terminally Truncated Human FUS Causes Extensive Changes in the Spinal Cord Transcriptome of Asymptomatic Transgenic Mice.

Authors:  Ekaterina A Lysikova; Sergei Funikov; Alexander P Rezvykh; Kirill D Chaprov; Michail S Kukharsky; Aleksey Ustyugov; Alexey V Deykin; Ilya M Flyamer; Shelagh Boyle; Sergey O Bachurin; Natalia Ninkina; Vladimir L Buchman
Journal:  Neurochem Res       Date:  2020-03-11       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.